Eisai's Rufinamide Estimated User Fee Deadline Is July 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.You may also be interested in...
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Firm's Nov. 16 filing addresses formatting issues that led to voluntary withdrawal earlier this month of initial NDA for the anti-epileptic and sets September 2006 PDUFA date.
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Firm's Nov. 16 filing addresses formatting issues that led to voluntary withdrawal earlier this month of initial NDA for the anti-epileptic and sets September 2006 PDUFA date.
Medicare Rx Formularies May Omit Lexapro Or Celexa, CMS Says
Both antidepressants are not needed on Part D drug formularies “since escitalopram is the component of citalopram that is responsible for the antidepressant effects,” CMS says. Iressa and Cerebyx may also be left off formularies despite the requirement that “all or substantially all” drugs in their categories be included.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: